AYTU BIOPHARMA, INC Segments Disclosure
Note 20 - Segment Information
The Company’s CODM, who is the Company’s Chief Executive Officer, allocates resources and assesses performance based on financial information of the Company. The CODM reviews financial information presented for each reportable segment for purposes of making operating decisions and assessing financial performance.
The Company manages and aggregates its operational and financial information in accordance with reportable segments: Rx and Consumer Health. The Rx Segment consists of the Company’s prescription products. The Consumer Health Segment contained the Company’s consumer healthcare products. For purposes of determining operating income or loss by segment, the Company allocates common expenses such as corporate administration, executive and board compensation, insurance, and fees associated with being a publicly traded entity, among others, to the Rx Segment. The Rx Segment also includes pipeline research and development. The CODM does not regularly review asset information by segment, accordingly, asset information is not provided by segment.
Select financial information for these segments is as follows:
| Rx | Consumer Health | Consolidated | ||||||||||
| | (in thousands) | |||||||||||
| Year Ended June 30, 2024 | | | | |||||||||
| | | | | |||||||||
| Net revenue | $ | 65,183 | $ | 15,819 | $ | 81,002 | ||||||
| Loss from operations | $ | (1,590 | ) | $ | (3,664 | ) | $ | (5,254 | ) | |||
| | | | | |||||||||
| Depreciation and amortization | $ | 5,909 | $ | 1,547 | $ | 7,456 | ||||||
| Stock-based compensation expense | $ | 2,373 | $ | 540 | $ | 2,913 | ||||||
| Restructuring costs | $ | 2,156 | $ | 209 | $ | 2,365 | ||||||
| | | | | |||||||||
| Year Ended June 30, 2023 | | | | |||||||||
| | | | | |||||||||
| Net revenue | $ | 73,799 | $ | 33,600 | $ | 107,399 | ||||||
| Loss from operations | $ | (7,358 | ) | $ | (9,707 | ) | $ | (17,065 | ) | |||
| | | | | |||||||||
| Depreciation and amortization | $ | 6,271 | $ | 1,116 | $ | 7,387 | ||||||
| Stock-based compensation expense | $ | 5,722 | $ | 324 | $ | 6,046 | ||||||
| Impairment expense | $ | 2,730 | $ | 2,975 | $ | 5,705 | ||||||
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2024 | Sep 26, 2024 | Showing above |
| 2023 | Oct 12, 2023 | |
| 2022 | Sep 27, 2022 | |
| 2021 | Sep 28, 2021 | |
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.